BTK is also instrumental in the development of chronic lymphocytic leukemia (CLL), with the current effective treatments including BTK inhibitors such as Ibrutinib (Woyach et al., 2014; Burger et al., 2017; Burger, 2019). The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.